[go: up one dir, main page]

WO2002092779A3 - Method for enriching tissues in long chain polyunsaturated fatty acids - Google Patents

Method for enriching tissues in long chain polyunsaturated fatty acids Download PDF

Info

Publication number
WO2002092779A3
WO2002092779A3 PCT/US2002/015747 US0215747W WO02092779A3 WO 2002092779 A3 WO2002092779 A3 WO 2002092779A3 US 0215747 W US0215747 W US 0215747W WO 02092779 A3 WO02092779 A3 WO 02092779A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acids
long chain
polyunsaturated fatty
tissues
enriching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/015747
Other languages
French (fr)
Other versions
WO2002092779A2 (en
Inventor
Marc E Surette
Kenneth M Tramposch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pilot Therapeutics Inc
Original Assignee
Pilot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pilot Therapeutics Inc filed Critical Pilot Therapeutics Inc
Priority to AU2002309931A priority Critical patent/AU2002309931A1/en
Publication of WO2002092779A2 publication Critical patent/WO2002092779A2/en
Publication of WO2002092779A3 publication Critical patent/WO2002092779A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method is disclosed for the in vivo enrichment of mammalian tissues in long chain n-3 polyunsaturated fatty acids by administering a source of stearidonic acid, preferably Echium oil, in an amount sufficient to effect such enrichment.
PCT/US2002/015747 2001-05-17 2002-05-17 Method for enriching tissues in long chain polyunsaturated fatty acids Ceased WO2002092779A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002309931A AU2002309931A1 (en) 2001-05-17 2002-05-17 Method for enriching tissues in long chain polyunsaturated fatty acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29158401P 2001-05-17 2001-05-17
US60/291,584 2001-05-17

Publications (2)

Publication Number Publication Date
WO2002092779A2 WO2002092779A2 (en) 2002-11-21
WO2002092779A3 true WO2002092779A3 (en) 2003-03-13

Family

ID=23120911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/015747 Ceased WO2002092779A2 (en) 2001-05-17 2002-05-17 Method for enriching tissues in long chain polyunsaturated fatty acids

Country Status (2)

Country Link
AU (1) AU2002309931A1 (en)
WO (1) WO2002092779A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095953A (en) * 2017-06-12 2017-08-29 张伟伟 A kind of Chinese medicine for treating pregnant depression

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519939A (en) * 2002-03-08 2005-07-07 モンサント テクノロジー エルエルシー Treatment and prevention of inflammatory diseases
EP2218334B1 (en) 2004-11-04 2016-09-28 Monsanto Technology LLC Processes for preparation of oil compositions
WO2007066216A2 (en) * 2005-12-09 2007-06-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fatty acids profile correlated to the propensity or risk of breast cancer
BRPI0708535A2 (en) * 2006-03-03 2011-05-31 Monsanto Technology Llc means for improving cardiovascular health
EP1835014B1 (en) 2006-03-14 2015-04-22 Oilseeds Biorefinery Corporation Oil extraction using fatty acid alkyl esters
CA2654303C (en) 2006-06-08 2016-07-26 The Iams Company Use of at least one polyphenol for promoting eye health
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
NO2384192T3 (en) * 2009-01-05 2018-03-24
KR101938055B1 (en) 2017-04-05 2019-01-14 성균관대학교산학협력단 A composition for treating, improving and preventing of artheriosclerosis comprising Gracilariopsis chorda ohmi extract or Gracilariopsis chorda ohmi fraction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178873A (en) * 1990-06-06 1993-01-12 Efamol Holdings Plc Essential fatty acid treatment
WO1999033355A2 (en) * 1997-12-23 1999-07-08 N.V. Nutricia Fat blend
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
WO2001017517A2 (en) * 1999-09-10 2001-03-15 Monsanto Technology, Llc Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer
US6331568B1 (en) * 1996-10-11 2001-12-18 Scotia Holdings Plc. Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178873A (en) * 1990-06-06 1993-01-12 Efamol Holdings Plc Essential fatty acid treatment
US6331568B1 (en) * 1996-10-11 2001-12-18 Scotia Holdings Plc. Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO1999033355A2 (en) * 1997-12-23 1999-07-08 N.V. Nutricia Fat blend
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
WO2001017517A2 (en) * 1999-09-10 2001-03-15 Monsanto Technology, Llc Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095953A (en) * 2017-06-12 2017-08-29 张伟伟 A kind of Chinese medicine for treating pregnant depression

Also Published As

Publication number Publication date
WO2002092779A2 (en) 2002-11-21
AU2002309931A1 (en) 2002-11-25

Similar Documents

Publication Publication Date Title
IL160012A0 (en) Modifying the fatty acid composition of cell membranes of organs and tissues
BRPI0418921A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a
WO2008018043A3 (en) Methods of improving bone health and muscle health
IS2180B (en) A pharmaceutical composition containing eicosapentaenoic acid and / or steridonic acid
ATE406808T1 (en) COMPOSITIONS CONTAINING SHORT AND LONG CHAIN FATTY ACIDS AND METHOD FOR THEIR USE FOR BODY WEIGHT CONTROL
WO2007070611A3 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
EP1682567A4 (en) Delta12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast
PT1296670E (en) THERAPEUTIC COMBINATIONS OF FATTY ACIDS
WO2004078166A3 (en) Use of omega-3-fatty acids in the treatment of diabetic patients
EP2392664A3 (en) Production of polyunsaturated fatty acids in oleaginous yeasts
WO2007136671A3 (en) Delta5 desaturase and its use in making polyunsaturated fatty acids
EA200701100A1 (en) OXYLIPINS FROM POLYUNSATURATED FATTY ACIDS WITH A LONG CHAIN AND METHODS FOR THEIR RECEPTION AND APPLICATION
WO2002081668A3 (en) Desaturase genes and uses thereof
WO2008129358A8 (en) Oil producing microbes and methods of modification thereof
CY1113437T1 (en) COMPOSITIONS WITH HEALTH AND NUTRITION CHARACTERISTICS CONTAINING DISTRIBUTED FATS AND PLANTS
EP1698685A4 (en) Fat composition
EP1682566A4 (en) Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
ATE384518T1 (en) COMPOSITIONS CONTAINING PHYTOSTEROL AND POLICOSANOLESTERS OF FATTY ACIDS TO REDUCE CHOLESTEROL AND TRIGLYCERIDE LEVELS
WO2002092779A3 (en) Method for enriching tissues in long chain polyunsaturated fatty acids
ATE542892T1 (en) DELTA-17 DESATURASES AND THEIR USE IN THE PRODUCTION OF POLYUNSATURATED FATTY ACIDS
EP1504677A4 (en) Body taste improver comprising long-chain highly unsaturated fatty acid and/or ester thereof and vegetable fat composition containing the same
BR0309089A (en) Dietary Methods for Performance Improvement in Dogs
SG149825A1 (en) Body taste improver comprising long-chain highly unsaturated fatty acid and/or ester thereof
ATE473285T1 (en) METHOD FOR PRODUCING GAMMA-LINOLENIC ACID FROM A CILIATES CULTURE BY ADDING SUITABLE PRECURSOR MOLECULES TO THE CULTURE MEDIUM
MXPA01007680A (en) Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP